healthcare's blog

The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. The North American nuclear medicine market is segmented into the US and Canada, based on country. The US is expected to account for the largest share and also register the highest CAGR during the forecast period.

According to the new market research report "North American Nuclear Medicine Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024", published by MarketsandMarkets™, the North American Radiopharmaceuticals Market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, at a CAGR of 4.1%.

Request Sample of Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108

The key factors driving the growth of this market are increasing incidence and prevalence of cancer & cardiac ailments and the initiatives to lessen the demand-supply gap of Mo-99.

Key Market Players

Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).

Cardinal Health (US) is one of the major players in the North American nuclear medicine market. Cardinal Health is a healthcare services company providing pharmaceutical and medical products & services to healthcare providers. Cardinal Health operates in the US, Canada, the British Virgin Islands, Malaysia, Singapore, the UK, Luxembourg, Thailand, Switzerland, Ireland, and Belgium through its 150 subsidiaries.

Curium (France) is another major player in the North American nuclear medicine market. Curium started its operations in 2017 through the union of two major players—IBA Molecular (France) and Mallinckrodt Pharmaceuticals (Ireland)—in the nuclear medicine market. Curium focuses on innovation, and it invested ~USD 3 million to build a new R&D laboratory

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108

GE Healthcare (US) has a huge network of radiopharmacies and a robust customer base in approximately 175 countries, primarily operating in North America, Europe, the Pacific Basin, the Americas, and the Middle East & Africa.

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the North American nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

• The key players in the industry and markets have been identified through extensive secondary research
• The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
• All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Request for Custom Research @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1108

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/north-american-nuclear-medicine-radiopharmaceuticals-market.asp

Visit Our Website: https://www.marketsandmarkets.com

Content Source: https://www.marketsandmarkets.com/PressReleases/north-american-nuclear-medicine-radiopharmaceuticals.asp

Global Pedicle Screw System Market guarantees you will remain better informed than your competition. This study provides the broader perspective of the market place with its comprehensive market insights and analysis which eases surviving and succeeding in the market. Global Pedicle Screw System market report through its market research helps improve and modify products so that the necessary changes to the future products can be made and more satisfaction is presented to the valuable customers.

Request for Free Sample Report @ 

https://www.marketsandmarkets.com/requestsample.asp?id=98811670

The Pedicle Screw Systems Market is expected to reach USD 724.23 million by 2023 from USD 538.64 million in 2018, at a CAGR of 6.1%.

The report analyzes and studies the major drivers, restraints, opportunities, and challenges of the Pedicle Screw System Market in North America, Europe, Asia Pacific, and the Rest of the World (RoW).  The high incidence of sports injuries, growing geriatric population, rising inclination of patients and hospitals towards minimally invasive surgeries, technological advancements in arthroscopy products, and an efficient reimbursement system in developed countries are some of the factors driving the growth of the market.

The increasing incidence of spinal cord injuries, increasing aging population, and technological advancements are major factors driving the growth of the Pedicle Screw Systems Market.

Polyaxial pedicle screw systems are expected to account for the largest market share

On the basis of product type, the Pedicle Screw Systems Market is segmented into monoaxial, polyaxial, and other pedicle screw systems. the polyaxial pedicle screw systems segment is expected to account for the largest share of the global Pedicle Screw Systems Market. The large share of this market segment can be attributed to the increasing prevalence of spinal cord disorders and product launches.

Browse in-depth TOC on "Pedicle Screw Systems Market"

66 - Tables 

36 - Figures 

110 - Pages 

View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/pedicle-screw-system-market-98811670.html

Open surgery is estimated to account for the largest share of the Pedicle Screw Systems Market

By surgery type, the Pedicle Screw Systems Market has been segmented into open surgery and minimally invasive surgery. the open surgery segment is expected to account for the largest share of the Pedicle Screw Systems Market due to the rising geriatric population, increasing incidence of spinal deformities, and technological advancements in spinal fusion surgeries.

The spinal degeneration segment is estimated to grow at the highest CAGR during the forecast period

By indication, the market includes spinal degeneration, spinal trauma, spinal deformities, and other indications. The spinal degeneration segment is estimated to register the highest CAGR during the forecast period. The high prevalence of degenerative spine disorders is expected to result in a growing volume of surgical procedures performed.

North America is estimated to command the largest share of the market

Based on region, the Pedicle Screw Systems Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global Pedicle Screw Systems Market.

Key Market Players

Key players in the Pedicle Screw Systems Market include DePuy Synthesis (US), Globus Medical (US), Zimmer Biomet (US), B. Braun (US), Medtronic (Ireland), and Stryker (US).

Speak to Our Analyst and gain crucial industry insights that will help your business grow:

https://www.marketsandmarkets.com/speaktoanalyst.asp?id=98811670

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Salgarkar

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Transplant Diagnostics Industry Overview

The report "Transplant Diagnostics Marketby Technology (PCR, NGS, Sanger Sequencing), Product(Instrument, Reagent, Software), Application(HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User, & Region - Global Forecasts to 2028", is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2022, at a CAGR of 7.4% during the forecast period.

Organ transplants have gradually improved over the past 20 years and typically produce excellent results in children and young adults. However, the proportion of elderly transplant patients with comorbidities is increasing, posing a greater challenge. When compared to dialysis, renal transplants increase patient survival, and patients with liver, heart, or lung diseases that are incurable must receive life-saving transplants. The activity of solid organ transplant programmes has been steadily increasing, but it still falls short of global needs and varies greatly between nations. Transplanting solid organs is crucial for advanced and established medical systems.

Gather more insights about the market drivers, restrains and growth of the Global Transplant Diagnostics Market

Molecular assay technologies segment to register a significant growth rate over the forecast period of 2022-2028

Based on Technology, molecular assay technologies are segmented to witness the highest growth during the forecast period. Molecular assay technologies are segmented into PCR-Based molecular assays and sequencing-based molecular assays. PCR-based molecular assays are further segmented into Real-time PCR, Sequence-specific primer, Sequence-specific Oligonucleotide and other PCR-based molecular assays.

Sequence-specific Oligonucleotide is growing at the highest CAGR of 9.5%.

The Reagents & Consumables holds the largest share in the Product and Service segment of the Transplant diagnostic market.

The reagents and consumables is projected to reach USD 5,131.0 million from USD USD 3,265.2 million in 2022 with the CAGR of 7.8%.

Based on End users, the transplant diagnostic market is segmented into Hospitals and Diagnostic centers, Research & Academic Institutes and Independent reference laboratories. The Independent reference laboratories segment accounted for the largest share of the transplant diagnostic market. The growing number of organ transplant procedures and growing number of diagnostic labs across emerging countries are helping the independent diagnostic centers to hold the largest share.

North America  to register major growth in the market during the forecast period

North America transplant diagnostic market is anticipated to register the highest growth over the forecast period of 2022 to 2028. North America accounted for the largest share of 45.5% of the transplant diagnostic market in 2022. This market is projected to reach USD 3.1 billion by 2028 from USD 2.0 billion in 2022, at a CAGR of 7.6% during the forecast period. North America holds 45.5% share of the total antimicrobial susceptibility testing market. The large share of North America can be attributed due to the growth in the geriatric population and the increase in infectious diseases., Asia-Pacific is expected to experience significant development.

Transplant Diagnostics Market Segmentation

This report categorizes the global transplant diagnostics market into following segments & sub-segments:

By Technology

• Molecular assay technologies
• Sequencing based molecular assays
• Non molecular assays technologies

By Product & Service

• Reagents & Consumables
• Instruments
• Software & Services

By Application

• Diagnostic application
• Research applications

By transplant type

• Solid Organ Transplantation
• Stem Cell transplantation
• Soft tissue transplantation
• Bone marrow transplantation

By End User

• Hospitals and Transplant centers
• Research &Academic Institutes
• Independent reference laboratories

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Market Share Insights

• In February 2023, BD received FDA approval for BD Onclarity HPV assay in the serology testing segment
• In March 2023 BioRad received AQAC International and AFNOR approval for its iQ-Check kits.
• Hoffmann-La Roche Ltd. unveiled Cobas Infinity edge, a cloud-based point-of-care platform that is available everywhere, in January 2022. Practitioners in the healthcare industry can manage patient data thanks to advanced technology. This has aided the business in diversifying its product offering.

Key Companies profiled:

Some prominent players in the global Transplant Diagnostics market include

·         Becton

·         Dickinson and Company

·         Biomerieux SA

·         Bio-Rad Laboratories

·         Inc.F-Hoffman-LA-Roche

·         and Thermo fisher Scientific.

Order a free sample PDFof the Transplant Diagnostics Market Intelligence Study, published by MarketsandMarkets

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

[email protected]

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020, at a CAGR of 27.6% during the forecast period. In 2019, Cerner Corporation (US), Allscripts Healthcare Solutions, Inc. (US), Epic Systems Corporation (US), and NextGen Healthcare (US) were some of the major players in the Ambulatory Surgical Centers market.

Key Market Players:

Some of the other prominent players operating in the Ambulatory Surgical Centers market are McKesson Corporation (US), GE Healthcare (US), Philips Healthcare (Netherlands), athenahealth, Inc. (US), Optum (US), Medical Information Technology, Inc. (MEDITECH) (US), eClinicalWorks (US), Advanced Data Systems Corporation (US), CureMD (US), HST Pathways (US), and Surgical Information Systems (US).

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182183086

Cerner Corporation (US) is one of the major players in the Ambulatory Surgical Centers market. The company has a diversified product portfolio, which includes a wide range of Ambulatory Surgical Centers IT products and services. Cerner’s position in the market is attributed to its active R&D activities and wide distribution footprint across the globe. To garner a larger share of the Ambulatory Surgical Centers market, the company continuously focuses on product launches and collaborations with other companies.

Allscripts Healthcare Solutions, Inc. (US) is one of the major players in the Ambulatory Surgical Centers market. Its dominance in the market can be attributed to its wide range of product offerings and its strong geographical footprint through strategic acquisitions and partnerships. Allscripts signed an agreement with Northwell Health for the development of next-generation, AI-powered electronic health records that would be used for better management of patient data among healthcare organizations. The company also focuses on R&D activities to develop its Ambulatory Surgical Centers that meet the customers’ demands.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=182183086

Recent Developments

• NextGen Healthcare launched NextGen Health Data Hub
• GE Healthcare launched Edison Datalogue and my. Cryochain software
• MEDITECH collaborated with Google to offer EHR data through the Google Cloud Platform. This helped to securely deliver patient data, enhance scalability, and facilitate interoperability.
• Epic Systems partnered with Teledoc Health to integrate Teledoc Health’s virtual care platform to Epic’s App Orchard that would help the company conduct telehealth video visits.

Ambulatory Surgical Centers Market Advantages:

1. Lower Costs: Ambulatory surgical centers are typically much less expensive than traditional hospital-based surgeries, making them an attractive option for many budget-conscious patients.
2. Shorter Wait Times: Patients who opt for an ambulatory surgical center are often able to be seen and treated much faster than in a hospital setting. This can be especially beneficial for those who are in urgent need of medical care.
3. Greater Privacy: Since many ambulatory surgical centers are smaller and more private than traditional hospitals, patients may feel more comfortable in the environment.
4. More Personalized Care: Many ambulatory surgical centers are staffed with highly-trained and experienced medical professionals who are able to provide patients with personalized care. This can lead to better treatment outcomes and a more positive overall experience.

Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=182183086

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

The report "Parkinsons Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast",

Parkinson’s Disease DrugsMarket Overview, Demand, New Opportunities & SWOT Analysis

The Parkinson’s Disease Drugs market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinsons disease and government funding for research.

Download PDF Brochure: @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247

This report aims to provide insights into the global Parkinson’s disease treatment market. It provides valuable information on the market classification by drug class, distribution channels, and patient care setting. Details on regional markets for these segments have also been presented in this report. In addition, leading players in the market are profiled to understand the strategies undertaken by them to be competitive in this market.

The Parkinsons disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%.

By drug class, the carbidopa/levodopa segment is estimated to dominate the market in 2017

On the basis of drug class, the Parkinsons disease therapeutic drugs market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO inhibitors, COMT inhibitors, anticholinergics, and other drugs. In 2017, the carbidopa/levodopa segment is expected to account for the largest share of the market. Carbidopa/levodopa drugs are more potent than most other drug classes are hence widely used in the treatment of Parkinson’s disease.

By distribution channel, the hospital pharmacies segment is estimated to hold the largest share of the market in 2017

By distribution channel, the Parkinsons disease therapeutic drugs market has been segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment is expected to account for the largest share of the market. The large share of this segment can primarily be attributed to the availability of a wide range of drugs in these facilities and the increasing number of patient visits to hospitals.

Browse complete Report along with TOC @ https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html

Hospitals to dominate the Parkinsons disease treatment market during the forecast period

The Parkinsons disease treatment market is classified by patient care settings into hospitals and clinics. In 2017, the hospital segment is expected to command the largest share and is estimated to grow at the fastest rate as compared to clinics segment. This market is mainly driven by robust healthcare services provided in hospitals and the presence of skilled neurologists in the hospitals.

Asia to offer lucrative growth opportunities

By region, the global Parkinsons disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While Europe is expected to hold the largest share of the market in 2017, Asia is expected to grow at the highest CAGR during the forecast period. Increasing number of players in the region and the rising aging population are some major factors driving the high growth of this regional segment.

Some of the major players operating in the Parkinsons disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany),  Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

Tevais one of the key players in the Parkinson’s disease treatment market. The company focuses on organic and inorganic strategies to strengthen its position in the Parkinson’s disease treatment market. For instance, in 2015, the company entered into an agreement with Takeda pharmaceutical company to commercialize rasagiline tablets in the Japan.  Moreover, the company received FDA approval for AZILECT drug to treat all stages of the Parkinson’s disease

Access Sample Copy of the Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=47265247

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Factors such as increasing investments in healthcare infrastructural development, technological innovations in ICU beds, increasing number of beds in private hospitals, and increasing volume of chronic care patients are expected to drive the growth of the medical beds market in the coming years. On the other hand, the declining number of beds in public hospitals may limit market growth to a certain extent. The growing trend of home care is expected to provide a wide range of opportunities to players in the Medical Beds Market.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=171671404

Market Dynamics

Drivers

• Increasing investments in healthcare infrastructural development
• Technological innovations in ICU beds
• Increasing number of beds in private hospitals
• Increasing volume of chronic care patients

Restraints

• Declining number of beds in public hospitals

Opportunities

• Growing trend of home care

Based on usage, the medical beds market is segmented into major four categories— acute care, psychiatric care and bariatric care, long-term care, and other beds (maternity and rehabilitative beds). The long-term care segment is expected to have the fastest-growing market during the forecast period owing to the increasing number of patients requiring long-term care.

Read More about Medical Beds Market:

https://www.marketsandmarkets.com/Market-Reports/hospital-beds-market-171671404.html

On the basis of type, the medical beds market is segmented into— manual beds, semi-electric beds, and electric beds. The electric beds segment is expected to dominate the medical beds market in 2017. The growing obesity rate is the major factor driving the demand for electric beds, as these are essential medical equipment in bariatric care. Moreover, the presence of favorable reimbursement policies in major markets such as the U.S. is also expected to support the growth of the electric beds market. For instance, Medicare provides a reimbursement of 7.5% on the purchase of new electric beds which can be used in home care settings. Such factors have increased the adoption rate of electric beds in home care and elderly care settings in developed regions such as the U.S.

Geographically, Europe is expected to account for the largest share of the global medical beds market in 2017, followed by North America. Compared to mature markets, the Asia-Pacific region is expected to grow at the highest CAGR in the forecast period. Growth in this regional segment is propelled by the growing healthcare infrastructure, rising number of contract manufacturing organizations (CMOs), and increasing number of bariatric population requiring care.

Major players operating in the medical beds market include Stryker Corporation (U.S.), Hill-Rom Holding, Inc. (U.S.), Getinge Group (Sweden), and Invacare Corporation (U.S.).

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=171671404

The global cell therapy technologies market is projected to reach USD 8.0 billion by 2027 from USD 4.0 billion in 2022, at a CAGR of 14.6% during the forecast period. Market growth is driven mainly by increasing research in regenerative medicine along with stem cell research, cancer research, and cell biology research.

Request for Sample PDF Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978

The global cell therapy technologies market is consolidated. The prominent players operating in this market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US).

Thermo Fisher Scientific

Thermo Fisher Scientific offers a complete and integrated portfolio of solutions and services for clinical science, laboratory research, and analysis. It operates in four business segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Its Life Sciences Solutions segment offers a wide range of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as the diagnosis of diseases.

Merck KGaA

Merck operates through three business segments, namely, Healthcare, Life Science, and Performance Materials. The Life Science segment offers life science products and services for research and diagnostic purposes. Merck offers products in the cell therapy technologies market through its Life Science segment.

Danaher Corporation

Danaher Corporation operates through three strategic segments—Environmental and Applied Solutions, Life Sciences, and Diagnostics. The Diagnostics segment offers a wide range of products through its key brands—SCIEX, Beckman Coulter, Leica Biosystems, Leica Microsystems, Radiometer, and Cepheid. Beckman Coulter and Cytiva, subsidiaries of Danaher Corporation, cater to the cell therapy technologies market. Beckman develops, manufactures, and markets products in automation, diagnostics, and chemistry.

Browse Complete Report along with TOC @  https://www.marketsandmarkets.com/Market-Reports/cell-therapy-technologies-market-213334978.html

The Asia Pacific region is the fastest-growing region of the cell therapy technologies market

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the cell therapy technologies market of the region is mostly driven by their low labor and manufacturing costs, which has drawn huge investments by biopharma giants to these countries.

Recent Developments

·         Thermo Fisher Scientific launched the first T-cell medium designed specifically for allogeneic cell therapy workflows.

·         Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The acquisition has led to the formation of a new business named Cytiva, a standalone operating company within Danaher's Life Sciences segment.

Buy-Now this Premium Report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=213334978

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

[email protected]

Particle TherapyIndustry Overview

Global particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137

Market growth is driven by factors such as growing adoption of particle therapy in clinical trials and the increasing number of particle therapy centers worldwide. Emerging markets are China India, Brazil, and South Africa are showing lucrative growth opportunities to market.

Covid-19 Impact on Economic Scenario in Particle Therapy Market

Globally, the outbreak of COVID-19 has impacted every aspect of the medical device industry, including particle therapy devices. From region to region, there is considerable variation in the management of particle therapy procedures during the COVID-19 pandemic. The particle therapy market is expected to be impacted due to the temporary postponement of various elective surgeries as governments and authorities seek to ensure the availability of resources for COVID-19 patients.

Particle Therapy Market Segmentation

Pediatric cancer defined for the largest share in the particle therapy market by cancer type

Based on cancer type, the particle therapy market is segmented into prostate cancer. pediatric cancer, lung cancer, breast cancer, head & neck cancer, and other cancers. The pediatric cancer segment is holds the largest share of 24.8% of the particle therapy market in 2021 with CAGR of 10.4% during the forecast period.

Products such as cyclotron accounted for the largest share in the particle therapy market by product type

Based on products & services, the particle therapy market is segmented into products and services. In 2021, products are estimated to account for the largest share of 78.6% of the particle therapy market.

Based on system, multi-room systems holds the largest share in the particle therapy

Based on the system, the particle therapy market is segmented into single-room and multi-room particle therapy systems. The multi-room systems segment is expected to account for the largest share (67.8%) of the particle therapy market.

Particle Therapy Regional Outlook

• North America
• Europe
• Asia pacific
• Latin america
• Middle east & Africa

Key Companies Profile & Market Share Insights

Prominent players in the particle therapy market include Varian Medical Systems, Inc. (US), IBA Worldwide (EU), Mevion Medical Systems (US), Provision Healthcare, LLC (US), Sumitomo Heavy Industries, Ltd. (Japan), Hitachi, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), Protom International, Inc. (US), Advanced Oncotherapy PLC. (EU), and Danfysik A/S (Denmark)

IBA is one of the leading players in the particle therapy market. Its Proton Therapy segment offers Proteus PLUS, a treatment room solution, and Proteus ONE, a single-room cancer treatment solution.

Order a free sample PDFof the Particle TherapyMarket Intelligence Study, published by MarketsandMarkets.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

[email protected]

Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays.

Hemato oncology is typically referred to as the science associated with the treatment, diagnosis, and prevention of blood-related diseases and cancers.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877

Market Segmentation

Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the hemato oncology testing market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population.

Based on end-user, the hemato-oncology testing market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests.

Regional Analysis

North America accounted for the largest share of the hemato oncology testing market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period.

Key Market Players

Some of the leading players in the hemato oncology testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).

Get Data as per your Format and Definition | REQUEST FOR CUSTOMIZATION @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=262472877

Expected Revenue Growth:

[116 Pages Report] The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period.

F. Hoffmann-La Roche Ltd. (Switzerland) was the leading player in the hemato-oncology testing market in 2018. The company offers a full range of tests for the diagnosis of hemato-oncology cancers, such as leukemia, lymphoma, and myeloma, among others.

Intraoperative Radiation Therapy Market Trends:

Global intraoperative radiation therapy market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period. The technological advancements such as the introduction of mobile IORT system, rising incidence of cancer, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy market.

Get Sample PDF: https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083

Key Market Players of Intraoperative Radiation Therapy Market:

ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton, Dickinson and Company (US), Sordina IORT Technologies (Italy), Varian Medical Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems Ltd. (UK)

ZEISS is among the pioneer companies that combined surgery with radiotherapy to develop and introduce intraoperative radiation therapy to the cancer treatment field. The flagship product of the company, INTRABEAM, is one of the most widely used IORT products across the globe. INTRABEAM is a revolutionary, intraoperative form of radiation therapy for early-stage breast cancers.

COVID-19 Impact on the global Intraoperative radiation therapy market

The intraoperative radiation therapy market was significantly impacted by the COVID-19 pandemic. Various screening, diagnostic, and surgical procedures were restricted or postponed at hospitals and cancer treatment centers, which resulted in disruptions in the cancer diagnosis as well as treatment market. The pandemic also impacted the availability of healthcare resources. Major regulatory authorities across the globe, such as the CDC, WHO, MHRA, TGA, and EMA, have identified cancer patients at a greater risk of contracting coronavirus disease than healthy adults.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083

Opportunity: Growing applications of IORT

Over the years, IORT has found significant applications as a breast-conserving treatment. Technological advancements in this field, coupled with the growing applications of IORT, has resulted in the increasing collaboration between a large number of manufacturers and research institutes to conduct clinical trials to study the applications and efficacy of IORT for other cancer types.

Recent Developments

·         Elekta AB launched Geneva, a universal gynecological applicator for brachytherapy.

·         Varian acquired Cancer Treatment Services International (CTSI), a US-based oncology solutions division that provides cancer care professional services to healthcare providers worldwide. The acquisition expanded Varian’s access to technology-driven cancer care .

Speak to our analyst for a discussion on the above findings: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245000083

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

[email protected]